United Laboratories International Holdings
The United Laboratories International Holdings Ltd is a Hong Kong-headquartered pharmaceutical company manufacturing intermediate antibiotics, active pharmaceutical ingredients, and finished formulations. The company produces bulk amoxicillin, ampicillin, insulin formulations, and specialized human prescription drugs across China. Main revenue drivers include commercial sales of intermediate antibiotics, bulk active pharmaceutical ingredients, and finished insulin and antibiotic formulations to domestic and export markets. The United Laboratories serves hospital networks, medical institutions, prescription pharmacies, and international pharmaceutical companies across mainland China, Europe, and Asia. The company holds a market-leading position in China for bulk antibiotic intermediates and human insulin production. Headquartered in Hong Kong, it is listed on the Hong Kong Stock Exchange.
6 of the funds FundTelligence covers report a position in United Laboratories International Holdings.
- Sector
- Health Care
- Country
- Hong Kong SAR China
- Funds holding it
- 6
Funds holding United Laboratories International Holdings
- Schroder ISF Emerging Markets Value — Schroders · 2.09 % (full portfolio disclosed, December 2025)
- Lannebo Global Småbolag — Lannebo · 0.59 % (full portfolio disclosed, June 2026)
- BlackRock iShares Healthcare Innovation UCITS ETF — BlackRock · 0.11 % (full portfolio disclosed, October 2026)
- Nordea Emerging Markets — Nordea Funds · 0.03 % (full portfolio disclosed, September 2026)
- Nordea Emerging Market Equities — Nordea Funds · 0.03 % (full portfolio disclosed, September 2026)
- Handelsbanken Global SMB Index Criteria — Handelsbanken · 0.01 % (full portfolio disclosed, October 2026)